（以前のダウ医薬部門→Merion Merrel Dow→Hechst→Aventis）
日本経済新聞 2003/3/12
米ダウ 日本で医薬製造受託 CBCと契約
改正薬事法施行により、医薬品の製造委託が２００５年から可能になるため、ダウは日本でも製造受託が成長分野になると判断した。
ダウ傘下のダウファーマはこのほど、野依良治・名古屋大学教授の持つ「不斉触媒合成技術」の工業実施権ライセンスを取得した。
Dowpharma Signs Agreement with
Japanese Distributor to Market Pharmaceutical Services in Japan
http://www.dow.com/pharma/news/20030314a.htm
Dowpharma, a business unit of The Dow Chemical Company signed an agreement with CBC Co. Ltd (Tokyo, Japan) to be its representative in marketing its pharmaceutical services to Japanese drug makers.
April 15, 2003 Financial Times
Dow Pharma to start contract manufacturing in Japan.Dow Pharma is to start contract drug manufacturing in Japan using facilities for specialty fine chemicals production acquired from Ascot of the UK in 2001. Dow Pharma has acquired the licence to the catalytic asymmetric synthesis technology of a Nobel Prize winning Japanese scientist and is expected to use the technology in the development of chiral selective high yield catalysts.
Pharmaceutical Services from Dow
Secures Exclusive Rights to DuPHOSTM Asymmetric（不斉）Hydrogenation Technology for
Pharmaceutical Applications
http://www.dow.com/pharma/news/20021204a.htm
The Pharmaceutical Services business unit of The Dow Chemical Company has secured exclusive rights to DuPontTM DuPHOSTM asymmetric hydrogenation technology, licensed from DuPont for pharmaceutical applications.
Chirotech Technology Limited originally licensed from DuPont in 1995 the exclusive rights for the commercial use of DuPHOSTM technology, and of related BPE and ferrocene-based ligands, for the pharmaceutical industry. Acquired by Dow in 2001 as part of the Ascot acquisition, Chirotech has been integrated into Dow's Pharmaceutical Services business.
In addition to well-established DuPHOSTM technology, we offer a broad range of complementary catalyst systems for asymmetric hydrogenation processes. In particular, under Chirotech's license from the Japan Science and Technology Corporation（科学技術振興事業団）, we have access to the powerful and versatile Noyori technology for ketone hydrogenation.”
Dowpharma http://www.dow.com/pharma/about/index.htm
Our business combines selected personnel and assets from Dow's original Contract Manufacturing Services business with those from acquired companies, including Chirotech Technology Limited (chiral chemo-catalysis and biocatalysis), Mitchell Cotts, Hampshire Chemical Corp. (hydrogen cyanide derivatives) and Dow Biopharmaceutical Contract Manufacturing Services, as well as other pharmaceutical services （such as ANGUS Chemical）within Dow.
Dow Declares Offer to Acquire
Ascot Wholly Unconditional
http://www.dow.com/dow_news/prodbus/2001/20010601a_pb.html
Dow UK plc, has declared its offer to acquire Ascot Plc wholly unconditional.
Dow plans to integrate Ascot's four businesses - Haltermann Custom Processing, Haltermann Products, Chirotech, and Mitchell Cotts - into its Custom & Fine Chemicals global business unit that also includes Dow Contract Manufacturing Services and ANGUS Chemical.
| ： | ・ | Haltermann Custom Processing: |
| Haltermann is a world leader in custom chemical processing, operating plants in Belgium, Germany, the United States and the United Kingdom. Haltermann works with many of the world's leading petrochemical and specialty chemical companies using continuous and batch distillation and reaction technology to provide its custom processing services. | ||
| ・ | Haltermann Products: Located in Germany with sales offices in Belgium, Romania, Sweden, France and the United Kingdom (as well as more than 40 agents and distributors), Haltermann's major customers are in the automotive, graphic arts, chemical and pharmaceutical industries. Its main products are printing ink distillates, ultra pure solvents, performance esters, reference fuels, low-boiling hydrocarbons and surfactants. |
|
| ・ | Chirotech: Chirotech is a leader in chiral technology, which enables the manufacture of drugs with higher efficacy and lower side effects. Its main products, which consist of single enantiomer scaffolds and building blocks for drug discovery, advanced intermediates and active pharmaceutical ingredients, are primarily sold to some of the world's major pharmaceutical companies. |
|
| ・ | Mitchell
Cotts: Mitchell Cotts' customers are major companies in the pharmaceutical and agricultural chemical industries for whom it manufactures higher value chemical materials under contract and also undertakes process development work. |
|
Hampshire Chemical Corp. http://www.dow.com/hampshire/
A wholly owned subsidiary of The Dow Chemical Company, Hampshire supplies specialty anionic surfactants based on Schotten-Baumann technology for personal care products and other applications, industrial dispersants, glycine, iminodiacetic acid, as well as hydrogen cyanide intermediates and derivatives, and custom synthesis.
http://informagen.com/Resource_Informagen/Full/9/12699.php
In 1998 Hampshire, formerly a member of the Sentrachem Group, became a wholly owned subsidiary of The Dow Chemical Company.
(In 1997 Sentrachem was purchased by Dow Corporation)
Dow Biopharmaceutical
Contract Manufacturing Services
http://www.dow.com/pharma/cap/bio.htm
Dowpharma offers a broad spectrum of technology capabilities, as well as development and manufacturing services for the production of recombinant proteins from microbial hosts or the formulation of liposomes for drug delivery.
ANGUS Chemical Company http://www.dow.com/angus/
More than Nitroparaffins . . . We
Deliver Great Solutions!
1999
Dow and TransCanada Pipelines Limited agree to a deal in which Dow will acquire CanStates Holdings, Inc., and its subsidiary, ANGUS Chemical Company. The acquisition is expected to help Dow reinforce its goals of expanding within the area of Performance Chemicals.